Sandoz Group AG (SDZNY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sandoz Group AG (SDZNY) trades at $83.97 with AI Score 51/100 (Grade B). Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars globally. Market cap: $36.34B, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for SDZNY: SDZNY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SDZNY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SDZNY: 4/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
Sandoz Group AG (SDZNY) Healthcare & Pipeline Overview
Sandoz Group AG, a global leader in generic pharmaceuticals and biosimilars, develops, manufactures, and markets affordable medicines. With a strong focus on small molecule pharmaceuticals, biosimilars, and anti-infectives, Sandoz leverages its established infrastructure to compete in the expanding generic drug market.
What Is the Investment Thesis for SDZNY?
Sandoz Group AG presents a notable research candidate within the generic pharmaceuticals and biosimilars market. With a market capitalization of $34.66 billion and a P/E ratio of 37.50, the company demonstrates financial stability. A gross margin of 47.2% indicates efficient operations. Growth catalysts include expanding biosimilar offerings and penetrating emerging markets. The company's established infrastructure and expertise in manufacturing complex generics provide a competitive advantage. Potential risks include increasing competition in the generic drug market and regulatory challenges. The company's commitment to innovation and strategic partnerships could drive long-term value creation.
Based on FMP financials and quantitative analysis
SDZNY Key Highlights
- Market capitalization of $34.66 billion reflects substantial investor confidence in Sandoz's market position.
- P/E ratio of 37.50 indicates investor expectations for future earnings growth.
- Gross margin of 47.2% demonstrates efficient cost management in pharmaceutical manufacturing.
- Dividend yield of 0.95% provides a steady income stream for investors.
- Beta of 0.33 suggests lower volatility compared to the overall market, indicating a relatively stable investment.
Who Are SDZNY's Competitors?
SDZNY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BAYRY Bayer AG | $10.36 | -0.38% | $40.71B | 51 |
| FSNUF Fresenius SE & Co. KGaA | $54.35 | +0.00% | $30.61B | 44 |
| HLNCF Haleon plc | $4.46 | -1.11% | $39.33B | 49 |
| JDHIF JD Health International Inc. | $5.85 | +0.00% | $18.69B | 51 |
| OTSKF Otsuka Holdings Co., Ltd. | $64.00 | +0.00% | $33.70B | 58 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SDZNY's Key Strengths?
- Established global presence and distribution network.
- Strong expertise in generic drug and biosimilar development.
- Efficient manufacturing capabilities and cost structure.
- Diverse product portfolio across various therapeutic areas.
What Are SDZNY's Weaknesses?
- Exposure to intense competition in the generic drug market.
- Dependence on patent expirations for revenue growth.
- Potential for regulatory challenges and pricing pressures.
- Limited presence in innovative branded pharmaceuticals.
What Could Drive SDZNY Stock Higher?
- Expansion of biosimilar product line, targeting new therapeutic areas and markets.
- Strategic partnerships to enhance manufacturing capabilities and market access.
- Potential regulatory approvals for new generic drugs and biosimilars.
- Increasing demand for affordable medicines in emerging markets.
What Are the Key Risks for SDZNY?
- Intense competition in the generic drug market, leading to pricing pressures.
- Regulatory changes and stricter approval processes for generic drugs and biosimilars.
- Patent litigation and intellectual property disputes.
- Currency fluctuations impacting revenue and profitability.
- Dependence on key suppliers for raw materials and manufacturing components.
What Are the Growth Opportunities for SDZNY?
- Expanding Biosimilar Portfolio: Sandoz has a significant opportunity to expand its biosimilar portfolio, capitalizing on the increasing demand for cost-effective alternatives to biologic drugs. The global biosimilars market is projected to reach $100 billion by 2028, driven by the expiration of patents on blockbuster biologics. Sandoz's expertise in biopharmaceutical manufacturing and regulatory approvals positions it to capture a substantial share of this market. Timeline: Ongoing, with new biosimilar launches expected in the next 3-5 years.
- Penetrating Emerging Markets: Emerging markets represent a significant growth opportunity for Sandoz, driven by increasing healthcare spending and a growing demand for affordable medicines. These markets often have less stringent regulatory requirements and lower barriers to entry for generic drugs. Sandoz can leverage its global presence and established distribution networks to penetrate these markets and expand its customer base. Timeline: Ongoing, with a focus on strategic partnerships and market-specific product development.
- Strategic Acquisitions and Partnerships: Sandoz can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its manufacturing capabilities, and access new markets. Acquiring smaller generic drug manufacturers or partnering with biotechnology companies can provide access to innovative technologies and strengthen Sandoz's competitive position. Timeline: Ongoing, with a focus on identifying synergistic opportunities that align with Sandoz's strategic goals.
- Focusing on Complex Generics: Sandoz can focus on developing and manufacturing complex generics, which have higher barriers to entry and offer greater profit margins compared to simpler generic drugs. These complex generics often require specialized manufacturing capabilities and regulatory expertise. Sandoz's established infrastructure and expertise in pharmaceutical manufacturing provide a competitive advantage in this area. Timeline: Ongoing, with a focus on investing in research and development and expanding manufacturing capabilities.
- Expanding into Value-Added Medicines: Sandoz can expand its offerings to include value-added medicines, which combine generic drugs with innovative delivery systems or formulations. These value-added medicines can provide improved patient outcomes and command higher prices compared to traditional generic drugs. Sandoz can leverage its expertise in pharmaceutical development and manufacturing to create innovative value-added medicines that meet the evolving needs of patients and healthcare providers. Timeline: Ongoing, with a focus on identifying unmet medical needs and developing innovative solutions.
What Opportunities Does SDZNY Have?
- Expanding biosimilar portfolio and market share.
- Penetrating emerging markets with affordable medicines.
- Strategic acquisitions and partnerships to enhance capabilities.
- Developing value-added medicines and innovative formulations.
What Threats Does SDZNY Face?
- Increasing competition from generic drug manufacturers.
- Pricing pressures and reimbursement challenges.
- Regulatory changes and stricter approval processes.
- Patent litigation and intellectual property disputes.
What Are SDZNY's Competitive Advantages?
- Established manufacturing infrastructure for generic drugs and biosimilars.
- Expertise in biopharmaceutical development and manufacturing.
- Global distribution network and market access.
- Strong regulatory expertise and compliance capabilities.
What Does SDZNY Do?
Sandoz Group AG, established in 1886 and headquartered in Rotkreuz, Switzerland, is a global leader in the development, manufacturing, and marketing of generic pharmaceuticals and biosimilars. The company's origins lie in the chemical and pharmaceutical industry, evolving over time to focus on providing affordable, high-quality medicines to patients worldwide. Sandoz develops and manufactures finished dosage forms of small molecule pharmaceuticals, catering to a broad range of therapeutic areas. Its portfolio includes a diverse array of generic drugs, addressing various medical needs. In addition to small molecule pharmaceuticals, Sandoz is a significant player in the biosimilars market, offering protein- or other biotechnology-based products that are similar to existing biologic drugs. The company also provides biotechnology manufacturing services, leveraging its expertise in biopharmaceutical production. Furthermore, Sandoz is involved in the development and manufacturing of anti-infectives, including active pharmaceutical ingredients and intermediates, with a primary focus on antibiotics. The company's global presence allows it to serve patients and healthcare providers in numerous countries, contributing to improved access to essential medicines.
What Products and Services Does SDZNY Offer?
- Develops and manufactures generic pharmaceuticals.
- Produces and markets biosimilars, offering alternatives to biologic drugs.
- Provides finished dosage forms of small molecule pharmaceuticals.
- Offers biotechnology manufacturing services.
- Develops and manufactures anti-infectives, including APIs and intermediates.
- Markets its products globally to healthcare providers and patients.
How Does SDZNY Make Money?
- Develops and manufactures generic drugs and biosimilars.
- Sells its products to wholesalers, distributors, and pharmacies.
- Generates revenue through product sales and manufacturing services.
What Industry Does SDZNY Operate In?
Sandoz Group AG operates within the global generic pharmaceuticals and biosimilars market, a sector characterized by increasing demand for affordable medicines. The industry is driven by patent expirations of branded drugs, creating opportunities for generic manufacturers. The biosimilars market is experiencing rapid growth, fueled by the increasing adoption of biologic therapies and the need for cost-effective alternatives. Competition is intense, with numerous players vying for market share. Sandoz's established infrastructure and expertise in manufacturing complex generics position it favorably in this competitive landscape.
Who Are SDZNY's Key Customers?
- Wholesalers and distributors of pharmaceutical products.
- Pharmacies and retail drug stores.
- Hospitals and healthcare providers.
- Governmental and non-governmental organizations.
SDZNY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SDZNY Latest News
No recent news available for SDZNY.
SDZNY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SDZNY.
Price Targets
Wall Street price target analysis for SDZNY.
SDZNY MoonshotScore
What does this score mean?
The MoonshotScore rates SDZNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Saynor
CEO
Richard Saynor serves as the CEO of Sandoz Group AG, leading a global team of 22049 employees. His career spans several decades in the pharmaceutical industry, with extensive experience in both generic and branded pharmaceuticals. Prior to joining Sandoz, he held leadership positions at various multinational pharmaceutical companies, where he was responsible for driving growth, innovation, and operational excellence. He has a proven track record of successfully launching new products, expanding market share, and building high-performing teams. His expertise encompasses strategic planning, commercial operations, and regulatory affairs.
Track Record: Under Richard Saynor's leadership, Sandoz Group AG has focused on expanding its biosimilar portfolio and penetrating emerging markets. He has overseen the launch of several new biosimilars, contributing to the company's growth in this key area. He has also implemented initiatives to improve operational efficiency and reduce costs. His strategic decisions have positioned Sandoz for long-term success in the competitive generic pharmaceuticals market.
Sandoz Group AG ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SDZNY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in Sandoz Group AG relatively easily.
- Home Market Ticker: SIX Swiss Exchange, Switzerland
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SDZN
SDZNY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk compared to investing in companies listed on major exchanges due to the lack of regulatory oversight and transparency. Companies in this tier may be newly formed, distressed, or have a limited operating history.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk management practices.
- Understand the risks associated with investing in OTC securities.
- Consult with a qualified financial advisor.
- Established history and track record in the pharmaceutical industry.
- Global presence and distribution network.
- Strong expertise in generic drug and biosimilar development.
- Listing on the SIX Swiss Exchange (SDZN).
- Market capitalization of $34.66 billion.
Common Questions About SDZNY (Healthcare)
What does Sandoz Group AG do?
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars on a global scale. The company focuses on providing affordable medicines across a variety of therapeutic areas, including cardiovascular, central nervous system, and pain management. Sandoz also offers biotechnology manufacturing services. The company's business model centers around developing and commercializing off-patent drugs, providing cost-effective alternatives to branded medications. Sandoz aims to improve access to essential medicines worldwide through its diverse product portfolio and global distribution network.
What are the main risks for SDZNY?
The main risks for Sandoz Group AG include intense competition in the generic drug market, which can lead to pricing pressures and reduced profitability. Regulatory changes and stricter approval processes for generic drugs and biosimilars could delay product launches and increase development costs. Patent litigation and intellectual property disputes pose a threat to the company's ability to commercialize certain products. Currency fluctuations can impact revenue and profitability, particularly in international markets. Dependence on key suppliers for raw materials and manufacturing components could disrupt the supply chain and increase costs. These risks should be carefully considered by investors.
How does Sandoz Group AG manage patent expiration risks?
Sandoz Group AG manages patent expiration risks through a multi-faceted approach. The company invests in research and development to create new generic versions of drugs coming off patent, ensuring a continuous pipeline of new products. Sandoz also focuses on developing biosimilars, which are similar to existing biologic drugs and offer a cost-effective alternative once the original patents expire. Furthermore, the company actively manages its product portfolio, diversifying its offerings across various therapeutic areas to reduce reliance on any single drug. Sandoz also engages in strategic partnerships and acquisitions to expand its product portfolio and access new technologies.
What are the key growth opportunities for SDZNY in healthcare?
Sandoz Group AG has several key growth opportunities within the healthcare sector. Expanding its biosimilar portfolio represents a significant growth driver, as biosimilars offer a cost-effective alternative to expensive biologic drugs. Penetrating emerging markets with affordable medicines presents another opportunity, as these markets often have a growing demand for generic drugs. Strategic acquisitions and partnerships can enhance Sandoz's capabilities and expand its product portfolio. Focusing on complex generics, which have higher barriers to entry, can also drive growth. Additionally, expanding into value-added medicines, which combine generic drugs with innovative delivery systems, can provide improved patient outcomes and command higher prices.
What are the key factors to evaluate for SDZNY?
Sandoz Group AG (SDZNY) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does SDZNY data refresh on this page?
SDZNY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SDZNY's recent stock price performance?
Sandoz Group AG (SDZNY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established global presence and distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SDZNY overvalued or undervalued right now?
Valuing Sandoz Group AG (SDZNY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be limited or delayed.
- Analyst coverage may be sparse due to OTC listing.